Eisai's Leqembi receives EU approval, revolutionizing Alzheimer's treatment

Eisai Co., Ltd. (TSE:4523) announced that the European Commission has granted Marketing Authorization (MA) in the European Union (EU) for Leqembi® (lecanemab) on April 15, 2025. Developed with BioArctic AB, Leqembi becomes the first approved therapy in the EU targeting the underlying cause of Alzheimer's for eligible patients with early-stage disease. Specifically, Leqembi is indicated for adults with mild cognitive impairment (MCI) and mild dementia due to Alzheimer's (early AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology. Eisai plans to disclose financial results on May 15, 2025. Eisai and Biogen co-commercialize the product.